Filtered By:
Source: Clinical Lung Cancer
Cancer: Cancer
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 21 results found since Jan 2013.
Pharmacological interventions for preventing atrial fibrillation after lung surgery: systematic review and meta-analysis
CONCLUSION: Current clinical evidence supports the effectiveness of pharmacological intervention with beta-blockers, amiodarone, magnesium sulfate, or calcium-channel blockers to reduce the incidence of POAF after lung surgery in patients with lung cancer. In the absence of contraindications, prophylaxis with beta-blockers seems to be the most effective of the treatments studied.PMID:36136141 | DOI:10.1007/s00228-022-03383-2
Source: Clinical Lung Cancer - September 22, 2022 Category: Cancer & Oncology Authors: Xiaomei Wang Demei Zhang Yanxia Ren Jingjing Han Guangling Li Xueya Guo Source Type: research
Active screening for lung cancer increases smoking abstinence in Australia
CONCLUSIONS: This study provides the first data on smoking cessation rates in Australian lung cancer screenees and supports screening as a teachable moment. We identify several factors that identify smokers who may require more intensive smoking cessation interventions and could be used to develop effective smoking cessation as part of lung cancer screening, tailored to individual risk profiles.PMID:36437500 | DOI:10.1111/ajco.13879
Source: Clinical Lung Cancer - November 28, 2022 Category: Cancer & Oncology Authors: Henry M Marshall Mounavi Vemula Karen Hay Elizabeth McCaul Linda Passmore Ian A Yang Rayleen V Bowman Kwun M Fong Source Type: research
Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma
CONCLUSION: For patients with mediastinal lymphoma excess mortality risks from CVD and second cancers remain clinically significant despite contemporary chemotherapy and photon-RT. Efforts to reduce the toxicity of combined modality treatment, for example, using DIBH, reduced margins and advanced RT, e.g. proton beam therapy, should be continued to further reduce potentially fatal treatment effects.PMID:36585562 | DOI:10.1007/s12094-022-03034-z
Source: Clinical Lung Cancer - December 30, 2022 Category: Cancer & Oncology Authors: Orla A Houlihan Georgios Ntentas David J Cutter Patricia Daly Charles Gillham Orla McArdle Frances K Duane Source Type: research
Healthcare systems data in the context of clinical trials - A comparison of cardiovascular data from a clinical trial dataset with routinely collected data
CONCLUSION: Concordance between datasets was lower than anticipated and the HSD used could not straightforwardly replace current trial practices, nor directly identify protocol-defined CVS events. Further work is required to improve the quality of HSD and consider event definitions when designing clinical trials incorporating HSD.PMID:36933612 | DOI:10.1016/j.cct.2023.107162
Source: Clinical Lung Cancer - March 18, 2023 Category: Cancer & Oncology Authors: Archie Macnair Matthew Nankivell Macey L Murray Stuart D Rosen Sally Appleyard Matthew R Sydes Sylvia Forcat Andrew Welland Noel W Clarke Stephen Mangar Howard Kynaston Roger Kockelbergh Abdulla Al-Hasso John Deighan John Marshall Mahesh Parmar Ruth E Lan Source Type: research
Development of a dynamic motion platform with two independent drive systems for radiotherapy
CONCLUSIONS: A new dynamic platform for radiation therapy with two drive systems capable of three-axis motion was developed, and the positional accuracy of the drive axes was confirmed to be less than 0.2 mm.PMID:36951306 | DOI:10.1002/acm2.13971
Source: Clinical Lung Cancer - March 23, 2023 Category: Cancer & Oncology Authors: Masahide Saito Hideyuki Kawakami Toshihiro Suzuki Hidekazu Suzuki Koji Ueda Hikaru Nemoto Naoki Sano Hiroshi Onishi Source Type: research
